Commitments and contingencies - Contingent milestone, royalty and other research and development commitments (Details)	12 Months Ended
Dec. 31, 2025 USD ($) payment
Commitments and contingencies
Royalties as a percentage of net sales in scenario one	1.00%
Royalties as a percentage of net sales in scenario two	2.00%
Percentage of sublicensing income for payments which are subject to triggering events	2.00%
Milestone payments made	$ 37,000
each time a Licensed Product is the subject of an approved IND
Commitments and contingencies
Payments for milestone subject to triggering events	$ 50,000
Number of payment per new drug candidate \| payment	1
each time a Licensed Product first enters Phase II human clinical trials
Commitments and contingencies
Payments for milestone subject to triggering events	$ 150,000
Number of payment per new drug candidate \| payment	1
each time a Licensed Product first enters Phase III human clinical trials
Commitments and contingencies
Payments for milestone subject to triggering events	$ 300,000
Number of payment per new drug candidate \| payment	1
each time a Licensed Product is the subject of a regulatory approval
Commitments and contingencies
Payments for milestone subject to triggering events	$ 1,000,000
Number of payment per new drug candidate	1

- Definition

Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.

+ References

No definition available.

+ Details

Name:	msle_CommitmentsAndContingenciesLineItems
Namespace Prefix:	msle_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the amount of milestone payments made.

+ References

No definition available.

+ Details

Name:	msle_MilestonePaymentsMade
Namespace Prefix:	msle_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Represents the number of payment per new drug candidate.

+ References

No definition available.

+ Details

Name:	msle_NumberOfPaymentPerNewDrugCandidate
Namespace Prefix:	msle_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the payments for milestone subject to triggering events.

+ References

No definition available.

+ Details

Name:	msle_PaymentsForMilestoneSubjectToTriggeringEvents
Namespace Prefix:	msle_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Represents the percentage of sublicensing income for payments which are subject to triggering events.

+ References

No definition available.

+ Details

Name:	msle_PercentageOfSublicensingIncomeForPaymentsWhichAreSubjectToTriggeringEvents
Namespace Prefix:	msle_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the royalties as a percentage of net sales in scenario one.

+ References

No definition available.

+ Details

Name:	msle_RoyaltiesAsPercentageOfNetSalesInScenarioOne
Namespace Prefix:	msle_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the royalties as a percentage of net sales in scenario two.

+ References

No definition available.

+ Details

Name:	msle_RoyaltiesAsPercentageOfNetSalesInScenarioTwo
Namespace Prefix:	msle_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	srt_StatementScenarioAxis=msle_EachTimeLicensedProductIsSubjectOfApprovedIndMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementScenarioAxis=msle_EachTimeLicensedProductFirstEntersPhaseIiHumanClinicalTrialsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementScenarioAxis=msle_EachTimeLicensedProductFirstEntersPhaseIiiHumanClinicalTrialsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementScenarioAxis=msle_EachTimeLicensedProductIsSubjectOfRegulatoryApprovalMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: